The molecular intelligence layer
KPCIRC + OnKommon
KPCIRC is the birthplace of OnKommon. Two organisations, deliberately separate: OnKommon does the assay and the interpretation; KPCIRC makes and owns the clinical decision.
The architecture
A report is not a decision
A raw variant list changes nothing on its own. What changes management is that list read against your disease, your stage, your prior treatment and your realistic options, by a clinician who then signs the plan.
No system, model or algorithm here prescribes or decides treatment. Every test is ordered, reviewed and signed by a named oncologist, and every board recommendation is countersigned by the physician clinical lead who carries clinical responsibility for it.
Sample to decision
Interpretation & evidence tiering
product family
Six molecular products
Which one applies depends on your disease, your stage and the decision actually in front of you. That choice is made in the consultation and at the board, it is clinical work, not an order form.
Blueprint Care
The comprehensive tumour profile, the option set for a new or advanced diagnosis, with evidence tiers attached to each finding.
Signature
Targeted and signature-level profiling where the decision turns on a defined set of markers rather than a whole-genome question.
Decipher
Interpretation of testing that already exists, including reports generated elsewhere, read back against the clinical picture.
Heritage
Germline and hereditary risk testing, always preceded by counselling and separate written consent, and always followed by a cascade plan for relatives.
Clear
Minimal residual disease assessment after treatment intended to cure, is anything still there, at a level nothing else can see?
Sentinel
Serial monitoring across a treatment course, is it working, and is anything changing before the scan shows it?
Product names, panels, turnaround times, specimen requirements and prices are set and published by OnKommon, not by KPCIRC. See onkommon.com for the current specification. Nothing on this page is a claim about any test's clinical performance.
× KPCIRC
Six places the two actually touch
Not a supplier relationship. Six specific mechanisms where a KPCIRC decision and an OnKommon result are the same piece of work seen from two sides.
Interpretation sits on the board
The genomic interpretation seat is filled with OnKommon interpretation, and our quorum rule forbids deciding a case with that seat empty. The lab is not downstream of the decision, it is in the room where the decision is made.
An oncologist orders and signs every test
No test is ordered by a coordinator, a portal or a template. A named KPCIRC oncologist selects the tier, documents the indication, signs the order, and signs the interpretation back into the clinical record.
Pathology gates the assay
Our onco-pathology desk assesses whether your tissue can actually support the test before it is sent, so you do not pay for an assay that returns "insufficient material". That check sits between the two organisations by design.
You do not pay twice for the same reasoning
Where a Decipher interpretation already exists, every written opinion is charged at 50% of the published fee. The interpretation work is done; the clinical reading is what remains.
Our research improves your report
The Indian Cancer Variant Atlas exists because global databases under-represent South Asian ancestry. Its output feeds interpretation directly, so the research changes what a report says, rather than sitting in a journal.
Separated on purpose
OnKommon bills you for the assay. KPCIRC bills you for the consultation, the interpretation review and the board. Neither takes a share of the other, and we never quote a blended price. That is what makes the tier decision clinical rather than commercial.
onkommon.com
KPCIRC is the birthplace of OnKommon. Two organisations, one clinical thread.
How the two work together
The board and the second-opinion desk run on this layer
- The tumour board's genomic seat is filled with OnKommon interpretation. The quorum rule forbids deciding a case with that seat empty.
- A molecular second opinion is that interpretation read back against your clinical picture by our panel, including for reports generated at another laboratory.
- The onco-pathology desk assesses whether your tissue is even adequate for testing, before you pay for an assay that will fail.
- Our research feeds interpretation back the other way: global variant databases under-represent South Asian ancestry, which is what the variant atlas programme exists to correct.
Billing, separated on purpose
- invoices you for the assay, at its own published rate.
- KPCIRC invoices you for the consultation, the interpretation review and the board.
- Neither takes a share of the other's fee.
- We never quote a single blended price mixing the two.
SHOT LATER · DIA-ONK-01 · SVG · light + dark
Testing is tiered, because cost-blind precision oncology is a metro import
Not every patient needs comprehensive profiling. Deciding who genuinely benefits from which tier is part of the clinical work you are already paying for, never an upsell.
Diagnostics & interpretation
Watch
Where your tissue actually goes
